Diving Into Ependymomas, Hard-to-Treat Pediatric Brain Tumors

Ependymomas are some of the most difficult-to-treat brain tumors. Mariella Filbin, MD, PhD, a neuro-oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is driven by a desire to find new therapies for these pediatric brain tumors. At the core of her work is an effort to uncover the events that shape tumor development. Defining how … Read more

Immunotherapy for Pediatric Solid Tumors: What’s New?

Medically reviewed by Natalie Collins, MD, PhD New treatments that spur the immune system against cancer have entered the clinic to combat some forms of pediatric blood cancers, such as acute lymphoblastic leukemia (ALL). One form of immunotherapy, CAR T cells, has been approved for children and young adults with ALL. In treating solid tumors … Read more

What is the Difference Between Gene Therapy and Immunotherapy?

Gene therapy and immunotherapy are both types of treatment for cancer and other diseases, and they have some points at which they intersect. But ultimately they represent different approaches to disease therapy. Most diseases aren’t caused by a single mutant gene — an alteration in the DNA sequence — but some mainly rare, inherited disorders, … Read more

What is a Biomarker?

A biomarker—short for “biological marker”—is something that can be objectively measured and is a sign of a normal or abnormal process, or a condition or disease. A biomarker can be a molecule found in the blood or other body fluids or tissues. Another type of biomarker is a genetic signature or “fingerprint”—a pattern of activity … Read more

Hodgkin Lymphoma Survivorship and Follow-Up Care

Adult Hodgkin lymphoma has one of the highest cure rates among all cancers. Still, the standard lymphoma therapies – including chemotherapy, radiation, surgery, and steroid therapy – may result in long-term side-effects beginning during treatment, and/or late-term effects arising years or decades after treatment. This is why check-ups and screenings are so important following treatment. … Read more

Who Should Be Treated with Immunotherapy?

There has been much excitement in recent years around new drugs that exploit the power of the body’s immune system to fight cancer. In some patients, even with advanced cancers, these immunotherapy treatments have slowed or halted the disease after standard treatments no longer worked, with remissions lasting several years and patients experiencing less severe … Read more

New Immunotherapy Therapy Approved for Lymphoma Patients

The Food and Drug Administration (FDA) approved a new kind of immunotherapy drug for adults and children with classical Hodgkin lymphoma who have relapsed after three or more prior lines of therapy. The approved drug, pembrolizumab (Keytruda), is part of a class of immunotherapy drugs called checkpoint inhibitors that block the PD-1 protein, which is … Read more